Crohn's Disease Drug Pipeline Analysis Report 2025

Crohn’s disease is a chronic inflammatory bowel disease (IBD) that affects the gastrointestinal tract, causing pain, diarrhea, fatigue, and weight loss. It accounts for a significant portion with approximately 6.8 million global IBD cases in 2017, including 0.83 million years of life lost and 1.02 million years of disability. The Crohn’s disease drug pipeline is expanding rapidly, driven by a growing focus on advanced biologics, small molecules, and personalized therapies. Recent developments emphasize improved efficacy and patient outcomes, with ongoing research expected to drive significant innovation in Crohn’s disease therapeutic products in the coming years.

Report Coverage

The Crohn’s Disease Drug Pipeline Insight Report by the publisher gives comprehensive insights into Crohn’s disease therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Crohn’s disease. The Crohn’s disease report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The Crohn’s disease pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with Crohn’s disease treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to Crohn’s disease.

Crohn’s Disease Drug Pipeline Outlook

Crohn’s disease is a chronic inflammatory bowel disease (IBD) that causes inflammation in the digestive tract. It can affect any part from the mouth to the anus, most commonly the small intestine. The exact cause is unknown, but it is believed to result from an abnormal immune response, genetic factors, and environmental triggers.

Crohn’s disease treatments focus on reducing inflammation, managing symptoms, and preventing complications. Common therapies include aminosalicylates, corticosteroids, immunomodulators, and biologics. Advanced treatments like targeted small molecules are emerging. In severe cases, surgery may be required to remove damaged tissue. Personalized therapies are becoming increasingly important for effective disease management.

Crohn’s Disease Epidemiology

Crohn’s disease is a significant form of inflammatory bowel disease (IBD) with increasing global prevalence. A 2023 study in the United States estimated 1.01 million Americans have Crohn’s disease, with a prevalence of 305 cases per 100,000 people. In Europe, the incidence ranges from 26 to 200 per 100,000, while in Asia and the Middle East, it varies from 1.37 to 1.5 per 100,000.

Crohn’s Disease - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of Crohn’s disease drug candidates based on several segmentations, including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Small Molecules
• Monoclonal Antibodies
• Biosimilars
• Gene Therapies
• Peptides
• Others

By Route of Administration

• Oral
• Parenteral
• Others

Crohn’s Disease - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total Crohn’s disease clinical trials.

Crohn’s Disease - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the Crohn’s disease pipeline analysis include small molecules, monoclonal antibodies, biosimilars, gene therapies, peptides, others. The Crohn’s disease report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for Crohn’s disease.

Crohn’s Disease Clinical Trials Therapeutic Assessment - Competitive Dynamics

The report for the Crohn’s disease drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed Crohn’s disease therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in Crohn’s disease clinical trials:

• Hoffmann-La Roche
• AstraZeneca
• AbbVie
• Janssen Pharmaceutical K.K.
• Tr1X, Inc.
• Alimentiv Inc.
• Sanofi
• Eli Lilly and Company
• Merck Sharp & Dohme LLC
• Agomab Spain S.L.
• Pfizer
• Antaros Medical

Crohn’s Disease Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for Crohn’s disease. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of Crohn’s disease drug candidates.

Drug: Vedolizumab

Vedolizumab is a gut-selective biologic used to treat adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC). The drug candidate is undergoing Phase IV clinical development, which is sponsored by Takeda. The study aims to evaluate symptom remission after 14 weeks of treatment. It works by blocking a4ß7 integrin, reducing gut inflammation. Participants receive intravenous doses initially, followed by subcutaneous injections.

Drug: Guselkumab

Guselkumab, developed by Janssen Pharmaceutical K.K., is in a Phase III study assessing its safety and efficacy in patients with moderately to severely active Crohn’s disease. This fully-human, dual-acting monoclonal antibody inhibits IL-23 and binds to CD64, reducing inflammation. By targeting IL-23, a key driver of immune-mediated diseases, it aims to enhance treatment outcomes.

Drug: TAK-279

TAK-279, developed by Takeda, is undergoing a Phase II clinical trial to assess its effectiveness and safety in treating moderately to severely active Crohn’s disease. The study aims to determine if three different doses of TAK-279 can reduce bowel inflammation and ulcers compared to a placebo over 12 weeks. TAK-279 is an oral therapy targeting immune pathways to alleviate inflammation.

Reasons To Buy This Report

The Crohn’s Disease Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for Crohn’s Disease. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into Crohn’s disease collaborations, regulatory environments, and potential growth opportunities.

Key Questions Answered in the Crohn’s Disease - Pipeline Insight Report

• Which companies/institutions are leading the Crohn’s disease drug development?
• What is the efficacy and safety profile of Crohn’s disease pipeline drugs?
• Which company is leading the Crohn’s disease pipeline development activities?
• What is the current Crohn’s disease commercial assessment?
• What are the opportunities and challenges present in the Crohn’s disease drug pipeline landscape?
• What is the efficacy and safety profile of Crohn’s disease pipeline drugs?
• Which company is conducting major trials for Crohn’s disease drugs?
• Which companies/institutions are involved in Crohn’s disease collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in Crohn’s disease?

This product will be delivered within 3-5 business days.